Literature DB >> 22240898

ATRX induction by mutant huntingtin via Cdx2 modulates heterochromatin condensation and pathology in Huntington's disease.

J Lee1, Y K Hong, G S Jeon, Y J Hwang, K Y Kim, K H Seong, M-K Jung, D J Picketts, N W Kowall, K S Cho, H Ryu.   

Abstract

Aberrant chromatin remodeling is involved in the pathogenesis of Huntington's disease (HD) but the mechanism is not known. Herein, we report that mutant huntingtin (mtHtt) induces the transcription of alpha thalassemia/mental retardation X linked (ATRX), an ATPase/helicase and SWI/SNF-like chromatin remodeling protein via Cdx-2 activation. ATRX expression was elevated in both a cell line model and transgenic model of HD, and Cdx-2 occupancy of the ATRX promoter was increased in HD. Induction of ATRX expanded the size of promyelocytic leukemia nuclear body (PML-NB) and increased trimethylation of H3K9 (H3K9me3) and condensation of pericentromeric heterochromatin, while knockdown of ATRX decreased PML-NB and H3K9me3 levels. Knockdown of ATRX/dXNP improved the hatch rate of fly embryos expressing mtHtt (Q127). ATRX/dXNP overexpression exacerbated eye degeneration of eye-specific mtHtt (Q127) expressing flies. Our findings suggest that transcriptional alteration of ATRX by mtHtt is involved in pericentromeric heterochromatin condensation and contributes to the pathogenesis of HD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22240898      PMCID: PMC3374076          DOI: 10.1038/cdd.2011.196

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  28 in total

1.  The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription.

Authors:  J S Steffan; A Kazantsev; O Spasic-Boskovic; M Greenwald; Y Z Zhu; H Gohler; E E Wanker; G P Bates; D E Housman; L M Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

2.  Neurodevelopmental defects resulting from ATRX overexpression in transgenic mice.

Authors:  Nathalie G Bérubé; Magdalena Jagla; Cecelia Smeenk; Yves De Repentigny; Rashmi Kothary; David J Picketts
Journal:  Hum Mol Genet       Date:  2002-02-01       Impact factor: 6.150

3.  Mutations in ATRX, encoding a SWI/SNF-like protein, cause diverse changes in the pattern of DNA methylation.

Authors:  R J Gibbons; T L McDowell; S Raman; D M O'Rourke; D Garrick; H Ayyub; D R Higgs
Journal:  Nat Genet       Date:  2000-04       Impact factor: 38.330

4.  Localization of a putative transcriptional regulator (ATRX) at pericentromeric heterochromatin and the short arms of acrocentric chromosomes.

Authors:  T L McDowell; R J Gibbons; H Sutherland; D M O'Rourke; W A Bickmore; A Pombo; H Turley; K Gatter; D J Picketts; V J Buckle; L Chapman; D Rhodes; D R Higgs
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

Review 5.  Transcriptional abnormalities in Huntington disease.

Authors:  Katharine L Sugars; David C Rubinsztein
Journal:  Trends Genet       Date:  2003-05       Impact factor: 11.639

6.  Heterochromatin and ND10 are cell-cycle regulated and phosphorylation-dependent alternate nuclear sites of the transcription repressor Daxx and SWI/SNF protein ATRX.

Authors:  Alexander M Ishov; Olga V Vladimirova; Gerd G Maul
Journal:  J Cell Sci       Date:  2004-07-13       Impact factor: 5.285

7.  Patient mutations alter ATRX targeting to PML nuclear bodies.

Authors:  Nathalie G Bérubé; Jasmine Healy; Chantal F Medina; Shaobo Wu; Todd Hodgson; Magdalena Jagla; David J Picketts
Journal:  Eur J Hum Genet       Date:  2007-10-24       Impact factor: 4.246

8.  A novel transcription regulatory complex containing death domain-associated protein and the ATR-X syndrome protein.

Authors:  Jun Tang; Shaobo Wu; Hongtu Liu; Rachael Stratt; Orr G Barak; Ramin Shiekhattar; David J Picketts; Xiaolu Yang
Journal:  J Biol Chem       Date:  2004-02-27       Impact factor: 5.157

9.  Aberrant histone acetylation, altered transcription, and retinal degeneration in a Drosophila model of polyglutamine disease are rescued by CREB-binding protein.

Authors:  J Paul Taylor; Addis A Taye; Catherine Campbell; Parsa Kazemi-Esfarjani; Kenneth H Fischbeck; Kyung-Tai Min
Journal:  Genes Dev       Date:  2003-06-15       Impact factor: 11.361

10.  Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells.

Authors:  F Trettel; D Rigamonti; P Hilditch-Maguire; V C Wheeler; A H Sharp; F Persichetti; E Cattaneo; M E MacDonald
Journal:  Hum Mol Genet       Date:  2000-11-22       Impact factor: 6.150

View more
  13 in total

1.  FUS(1-359) transgenic mice as a model of ALS: pathophysiological and molecular aspects of the proteinopathy.

Authors:  Sergei Y Funikov; Alexander P Rezvykh; Pavel V Mazin; Alexey V Morozov; Andrey V Maltsev; Maria M Chicheva; Ekaterina A Vikhareva; Mikhail B Evgen'ev; Aleksey A Ustyugov
Journal:  Neurogenetics       Date:  2018-07-07       Impact factor: 2.660

2.  Decreased FAK activity and focal adhesion dynamics impair proper neurite formation of medium spiny neurons in Huntington's disease.

Authors:  Hae Nim Lee; Seung Jae Hyeon; Heejung Kim; Kyoung Mi Sim; Yunha Kim; Jeongmin Ju; Junghee Lee; Yingxiao Wang; Hoon Ryu; Jihye Seong
Journal:  Acta Neuropathol       Date:  2022-07-20       Impact factor: 15.887

3.  Epigenetic dysregulation of hairy and enhancer of split 4 (HES4) is associated with striatal degeneration in postmortem Huntington brains.

Authors:  Guang Bai; Iris Cheung; Hennady P Shulha; Joana E Coelho; Ping Li; Xianjun Dong; Mira Jakovcevski; Yumei Wang; Anastasia Grigorenko; Yan Jiang; Andrew Hoss; Krupal Patel; Ming Zheng; Evgeny Rogaev; Richard H Myers; Zhiping Weng; Schahram Akbarian; Jiang-Fan Chen
Journal:  Hum Mol Genet       Date:  2014-12-05       Impact factor: 6.150

Review 4.  Nucleolar dysfunction in Huntington's disease.

Authors:  Junghee Lee; Yu Jin Hwang; Hyun Ryu; Neil W Kowall; Hoon Ryu
Journal:  Biochim Biophys Acta       Date:  2013-10-31

5.  Discovering chromatin motifs using FAIRE sequencing and the human diploid genome.

Authors:  Chia-Chun Yang; Michael J Buck; Min-Hsuan Chen; Yun-Fan Chen; Hsin-Chi Lan; Jeremy J W Chen; Chao Cheng; Chun-Chi Liu
Journal:  BMC Genomics       Date:  2013-05-08       Impact factor: 3.969

Review 6.  Transcription, epigenetics and ameliorative strategies in Huntington's Disease: a genome-wide perspective.

Authors:  Luis M Valor
Journal:  Mol Neurobiol       Date:  2014-05-01       Impact factor: 5.590

7.  Dysfunction of X-linked inhibitor of apoptosis protein (XIAP) triggers neuropathological processes via altered p53 activity in Huntington's disease.

Authors:  Seung Jae Hyeon; Jinyoung Park; Junsang Yoo; Su-Hyun Kim; Yu Jin Hwang; Seung-Chan Kim; Tian Liu; Hyun Soo Shim; Yunha Kim; Yakdol Cho; Jiwan Woo; Key-Sun Kim; Richard H Myers; Hannah L Ryu; Neil W Kowall; Eun Joo Song; Eun Mi Hwang; Hyemyung Seo; Junghee Lee; Hoon Ryu
Journal:  Prog Neurobiol       Date:  2021-06-21       Impact factor: 11.685

Review 8.  PML in the Brain: From Development to Degeneration.

Authors:  Erica Korb; Steven Finkbeiner
Journal:  Front Oncol       Date:  2013-09-17       Impact factor: 6.244

9.  ESET methylates UBF at K232/254 and regulates nucleolar heterochromatin plasticity and rDNA transcription.

Authors:  Yu Jin Hwang; Dohyun Han; Ki Yoon Kim; Sun-Joon Min; Neil W Kowall; Liu Yang; Junghee Lee; Youngsoo Kim; Hoon Ryu
Journal:  Nucleic Acids Res       Date:  2013-11-14       Impact factor: 16.971

Review 10.  Neuroprotective effects of psychotropic drugs in Huntington's disease.

Authors:  Edward C Lauterbach
Journal:  Int J Mol Sci       Date:  2013-11-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.